Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.
Proc. Natl. Acad. Sci. U.S.A., Jul;109(28):11252-7 (2012)
The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis.
Cancer Epidemiol. Biomarkers Prev., Sep;21(9):1497-509 (2012)
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.
J. Clin. Oncol., Dec;29(35):4682-7 (2011)
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.
Lancet Oncol., Feb;13(2):189-95 (2012)
The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer.
Prostate., Jul;72(10):1093-103 (2012)
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Sci Transl Med., Apr;4(128):128ra39 (2012)
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality.
J. Urol., Jun;187(6):2068-73 (2012)
Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.
Cancer Epidemiol. Biomarkers Prev., Jul;19(7):1871-8 (2010)
Secondary hormonal therapy in men with castration-resistant prostate cancer.
Clin Genitourin Cancer., Dec;9(2):95-103 (2011)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N. Engl. J. Med., Jul;363(5):411-22 (2010)
Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.
Clin. Cancer Res., Nov;16(21):5244-51 (2010)
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
JAMA., Dec;304(21):2373-80 (2010)
Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.
Clin. Cancer Res., Mar;17(6):1546-52 (2011)
The genomic complexity of primary human prostate cancer.
Nature., Feb;470(7333):214-20 (2011)
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.
Cancer Prev Res (Phila)., May;4(5):719-28 (2011)
mRNA expression signature of Gleason grade predicts lethal prostate cancer.
J. Clin. Oncol., Jun;29(17):2391-6 (2011)
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.
J. Clin. Oncol., Jun;29(17):2378-85 (2011)
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
J. Clin. Oncol., Jun;29(18):2565-73 (2011)
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
Ann. Oncol., May;23(5):1234-40 (2012)
Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
Cancer Res., Jul;69(13):5568-74 (2009)